NEW YORK (GenomeWeb News) –Harvard University spin-out company Auguron Biosciences has licensed its Nucleic Acid Programmable Protein Array (NAPPA) technology to Proteomika, a subsidiary of Progenika Biopharma.
 
Under the agreement, Proteomika may use the NAPPA technology at its facilities for in its autoimmune research and service programs, and it may exercise an option to negotiate an exclusive license to NAPPA within the field of biomarker discovery for inflammatory bowel disease and lupus.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.